Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Rossella Medori has been named chief medical officer of Accure Therapeutics. Medori was formerly a European medical director at Janssen-Cilag.
Clinical-stage biopharmaceutical company Arcellx has appointed Rami Elghandour to CEO. Elghandour was most recently CEO of Nevro.
Aspen Neuroscience has appointed Damien McDevitt, former CEO of Akcea Therapeutics, to president and CEO.
Amir Reichman has been appointed CEO of BiondVax. Reichman comes to BiondVax from GlaxoSmithKline Vaccines, where he served as head of global vaccines, engineering core technologies and asset management.
Elevian has appointed Christopher Dale to head of protein manufacturing and chemistry, manufacturing and controls. Dale was previously head of microbial technology at Lonza and vice president of technology at Cambrex Bio Science.
EXACT Therapeutics has named Hilary McElwaine-Johnn its chief medical officer. McElwaine-Johnn was most recently chief medical officer at Karus Therapeutics.
Philip Vickers has been named CEO of Faze Medicines. Vickers was previously the president and CEO of Northern Biologics.
January Therapeutics has brought on Steven Rosen as chief medical adviser to support clinical development of the company’s JNTX-101 and JNTX-104 programs. Rosen will continue to serve as provost and chief scientific officer of the City of Hope National Medical Center.
Ronald Marcus has been named senior vice president of medical at Karuna Therapeutics. Marcus was formerly the chief medical officer at Terran Biosciences.
Kinarus has found its newest chief medical officer in Thierry Fumeaux, former chief doctor at Nyon Hospital in Switzerland.
Qasim Rizvi has been named CEO of KSQ Therapeutics. Most recently, Rizvi was senior vice president of operations and chief commercial officer at Kiniksa Pharmaceuticals.
Christophe Maréchal has been named interim CEO of Mithra. Maréchal was most recently the company’s chief financial officer.
Qiutang Li has been named chief scientific officer of Neurophth Therapeutics. Li was most recently a professor at the University of Louisville School of Medicine.
Chris Bond, former vice president of cellular Engineering at Kite Pharma, has been named senior vice president of preclinical and translational sciences at Notch Therapeutics.
QureTech Bio has appointed Helén Fält to CEO. Fält was recently the company’s business coach at Umeå Biotech Incubator.
Susannah Cantrell has been named chief business officer of Second Genome. Formerly, Cantrell was executive vice president and chief commercial officer at Tricida. Second Genome has also hired Preeti Gupta Lal to take on the role of chief scientific officer. Lal was recently vice president of development sciences and translational medicine at Alladapt Immunotherapeutics.
Timber Pharmaceuticals has appointed Alan Mendelsohn to chief medical officer. Mendelsohn previously served as associate vice president of dermatology medical affairs at Sun Pharmaceuticals Industries.
Anil Singhal, former CEO of Adicet Bio, has been appointed CEO of Trishula Therapeutics.
Biotech company VarmX has appointed Gerard Short to chief medical officer. Short previously held the position of senior vice president of medical science at Freeline Therapeutics.
ViaCyte has appointed Michael Yang to president and CEO. Yang most recently served as executive vice president and chief commercial officer at Acadia Pharmaceuticals.
Diem Nguyen has taken the helm of Xalud Therapeutics as its newest CEO. Most recently, Nguyen served as executive vice president of Biopharma at PPD.
Ellison Humphrey has been named chief transformation officer at Zimmer Biomet. Previously, Humphrey held the role of vice president of enterprise excellence and business transformation at Medtronic.